Unknown NA INTERVENTIONAL 2-arm NCT02187081

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study.(REASSESS)

Sponsor: Southwest Hospital, China

Conditions HCC

Interventions Radiofrequency ablation radiofrequency ablation plus Sorafenib

Updated 7 times since 2017 Last updated: Mar 27, 2017 Started: Mar 15, 2017 Primary completion: Dec 31, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates HCC and is currently ongoing. Southwest Hospital, China leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Apr 2019 — Jan 2021 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Recruiting NA

▶ Show 2 earlier versions

Apr 2017 — Jun 2018 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting · Phase: PHASE3 → NA
Jan 2017 — Apr 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Southwest Hospital, China

Data source: Southwest Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China